BALAXI — Balaxi Pharmaceuticals Share Price
Last trade - 00:00- IN₹1.14bn
- IN₹1.57bn
- IN₹2.70bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.46 | ||
| Price to Tang. Book | 0.53 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.41 | ||
| EV to EBITDA | 17.37 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 2.37% | ||
| Return on Equity | 1.01% | ||
| Operating Margin | 2.32% | ||
Financial Summary
| Year End 31st Mar | Unit | 2022 | 2023 | 2024 | 2025 | 2026 | 2027E | 2028E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 2,793.88 | 3,364.33 | 2,412.94 | 2,925.61 | 2,701.74 | n/a | n/a | 3.15% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +24.96 | -4.73 | -51.76 | +3.66 | -94.21 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Balaxi Pharmaceuticals Limited is an India-based company. The Company operates as an intellectual property right (IPR)-based pharmaceutical company. The Company primarily operates in frontier markets across the Americas, Africa and the Caribbean islands. The Company is focusing on frontier markets, with a growing portfolio of drugs across multiple therapeutic segments. It is engaged in International Wholesale Distribution of Pharmaceuticals. The Company’s products include Anti-biotic, Analgesic, Medical Device, Vitamins, Anti-Malaria, Erectile Dysfunction, Hypertension, Anti-Asthma, Steroid, Anti-Helminthic, Anti-Ulcer, Hygiene, Anticholinergic, Dietary Supplement, Diuretic, Hormone, Anti-Emetic, Bronchodilator, Local Anesthetic, Anemia, Anti-Diarrhea, Antihistamine, Hypotension, Antacid, Anti-Tuberculosis, Insect Repellents, and Laxative. Its Boadent brand includes anticavity dental toothpaste. Its subsidiaries are Balaxi Global DMCC, Dubai and Balaxi healthcare Ecuador.
Directors
- Ashish Maheshwari CHM
- Amol Mantri CFO
- Nidhin Jose CCO
- Chinta Shalini CCO
- Jignesh Shah CTR
- Ram Chawla OTH
- Bharat Jawarani OTH
- Manish Jumnani OTH
- Karan Kapoor OTH
- Paridhi Maheshwari OTH
- Pranav Maheshwari OTH
- Laksh Shewakramani OTH
- Pankaj Singh OTH
- Minoshi Maheshwari NED (49)
- Kunal Bhakta NID (39)
- Gandhi Gamji NID (51)
- Purnima Kamble NID (49)
- M.Srinivas Rao NID (61)
- Last Annual
- March 31st, 2026
- Last Interim
- June 30th, 2026
- Incorporated
- September 28th, 1942
- Public Since
- November 30th, 2015
- No. of Shareholders
- 15,176
- No. of Employees
- 69
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 54,488,750
- Address
- Plot No: 409, 3rd Floor,Maps Towers, HYDERABAD, 500096
- Web
- https://balaxipharma.in/
- Phone
- +91 4023555300
- Auditors
- P. Murali & Co.
Latest News for BALAXI
Upcoming Events for BALAXI
Similar to BALAXI
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
As of Today at 19:30 UTC, shares in Balaxi Pharmaceuticals are trading at IN₹20.91. This share price information is delayed by 15 minutes.
Shares in Balaxi Pharmaceuticals last closed at IN₹20.91 and the price had moved by -51.69% over the past 365 days. In terms of relative price strength the Balaxi Pharmaceuticals share price has underperformed the S&P BSE 100 Index by -45.57% over the past year.
There is no consensus recommendation for this security.
Find out moreBalaxi Pharmaceuticals does not currently pay a dividend.
Balaxi Pharmaceuticals does not currently pay a dividend.
Balaxi Pharmaceuticals does not currently pay a dividend.
To buy shares in Balaxi Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of IN₹20.91, shares in Balaxi Pharmaceuticals had a market capitalisation of IN₹1.14bn.
Here are the trading details for Balaxi Pharmaceuticals:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: BALAXI
Based on an overall assessment of its quality, value and momentum Balaxi Pharmaceuticals is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Balaxi Pharmaceuticals. Over the past six months, its share price has underperformed the S&P BSE 100 Index by -17.53%.
As of the last closing price of IN₹20.91, shares in Balaxi Pharmaceuticals were trading -10.73% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Balaxi Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at IN₹20.91.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Balaxi Pharmaceuticals' management team is headed by:
- Ashish Maheshwari - CHM
- Amol Mantri - CFO
- Nidhin Jose - CCO
- Chinta Shalini - CCO
- Jignesh Shah - CTR
- Ram Chawla - OTH
- Bharat Jawarani - OTH
- Manish Jumnani - OTH
- Karan Kapoor - OTH
- Paridhi Maheshwari - OTH
- Pranav Maheshwari - OTH
- Laksh Shewakramani - OTH
- Pankaj Singh - OTH
- Minoshi Maheshwari - NED
- Kunal Bhakta - NID
- Gandhi Gamji - NID
- Purnima Kamble - NID
- M.Srinivas Rao - NID